Gainers
- NeuroMetrix (NASDAQ:NURO) stock moved upwards by 29.0% to $3.65 during Friday's after-market session. This security traded at a volume of 455.8K shares come close, making up 519.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $26.0 million.
- Aptinyx (NASDAQ:APTX) stock moved upwards by 12.55% to $0.39. The company's market cap stands at $26.4 million.
- Lipocine (NASDAQ:LPCN) shares increased by 9.89% to $0.5. The market value of their outstanding shares is at $44.2 million.
- CNS Pharmaceuticals (NASDAQ:CNSP) stock rose 8.97% to $0.21. The company's market cap stands at $8.4 million.
- Exicure (NASDAQ:XCUR) stock increased by 8.23% to $1.84. The market value of their outstanding shares is at $9.1 million.
- Mainz Biomed (NASDAQ:MYNZ) shares moved upwards by 7.83% to $7.02. The market value of their outstanding shares is at $101.6 million.
Losers
- Inventiva (NASDAQ:IVA) shares fell 18.9% to $5.72 during Friday's after-market session. Inventiva's trading volume hit 355.8K shares by close, accounting for 4289.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $241.0 million.
- Kala Pharmaceuticals (NASDAQ:KALA) stock fell 7.34% to $0.25. The market value of their outstanding shares is at $18.3 million.
- Acorda Therapeutics (NASDAQ:ACOR) shares decreased by 5.41% to $0.35. The company's market cap stands at $8.5 million.
- Heron Therapeutics (NASDAQ:HRTX) stock decreased by 5.26% to $3.97. The market value of their outstanding shares is at $471.4 million.
- Unity Biotechnology (NASDAQ:UBX) stock decreased by 4.47% to $0.37. At the close, Unity Biotechnology's trading volume reached 51.1K shares. This is 1.3% of its average volume over the last 100 days. The company's market cap stands at $51.9 million.
- Baudax Bio (NASDAQ:BXRX) shares fell 4.3% to $0.22. This security traded at a volume of 74.4K shares come close, making up 4.5% of its average volume over the last 100 days. The company's market cap stands at $1.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
